Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Current Leases (2019 - 2025)

Protagonist Therapeutics' Current Leases history spans 7 years, with the latest figure at $2.3 million for Q4 2025.

  • For Q4 2025, Current Leases rose 347.65% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $2.3 million, up 347.65%, while the annual FY2025 figure was $2.3 million, 347.65% up from the prior year.
  • Current Leases for Q4 2025 was $2.3 million at Protagonist Therapeutics, up from $2.2 million in the prior quarter.
  • Across five years, Current Leases topped out at $2.6 million in Q1 2023 and bottomed at $462000.0 in Q1 2024.
  • The 5-year median for Current Leases is $2.2 million (2021), against an average of $1.9 million.
  • The largest annual shift saw Current Leases plummeted 82.22% in 2024 before it soared 347.65% in 2025.
  • A 5-year view of Current Leases shows it stood at $2.2 million in 2021, then grew by 14.32% to $2.5 million in 2022, then tumbled by 54.63% to $1.1 million in 2023, then tumbled by 55.3% to $510000.0 in 2024, then skyrocketed by 347.65% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Current Leases are $2.3 million (Q4 2025), $2.2 million (Q3 2025), and $2.2 million (Q2 2025).